Edward Cooper Stites, M.D., Ph.D.

Institution: The Salk Institute for Biological Studies

Project: Targeted Inhibition of Mutant and Wild-type RAS in KRAS G12C Lung Cancer

Grant(s): Lung Cancer Discovery Award

When the KRAS gene is mutated it can cause normal cells to become cancerous. Approximately one-third of lung cancer patients have a mutation in the KRAS gene, and patients with such a mutation have a worse prognosis than those who do not. The most common KRAS mutation is known as “KRAS G12C.” A major new discovery in lung cancer treatment is the development of drugs that specifically target KRAS G12C. These drugs are now in clinical trials. Although there is great promise for these agents, it is widely expected that these drugs will need to be combined with other anti-cancer drugs to offer maximal benefit. Our study combines computational methods with traditional experimental approaches to investigate our hypothesis that targeting non-mutant RAS proteins along with KRAS G12C mutants will be an achievable and useful treatment strategy.

Freedom From Smoking Facilitator Training - Virtual
Online, NY | Dec 08, 2020
LUNG FORCE Walk
New York, NY | May 22, 2021